Washington, DC (UroToday.com) The optimal duration of surveillance for bladder cancer (BC) following radical cystectomy (RC) is unknown.
Washington, DC (UroToday.com) New treatment options for patients with BCG-refractory non-muscle invasive bladder cancer (NMIBC) are sorely needed. In this session, Dr. McKiernan commenced with a discussion of targeted therapies. Pre-clinically, murine models with inactivated PTEN and p53 demonstrate upregulation of the mTOR pathway. Such animals reliably form invasive bladder cancer. Inhibition of mTOR in these models reduced burden of disease. A phase 1 trial of nanoparticle albumin bound
Washington, DC (UroToday.com) Dr. Siamak Daneshmand presented data on enhanced recovery after surgery (ERAS) protocols in cystectomy patients in this morning’s session on bladder cancer. The goals of ERAS are to reduce complication rates and length of stay (LOS) without increasing readmission rates.
Washington, DC (UroToday.com) In this morning’s bladder cancer session, Dr. Dipen Parekh opened the debate between open (ORC) and robotic radical cystectomy (RALRC) with evidence in favor of RALRC. A comparison of variables between the two approaches showed that EBL, transfusion requirement, narcotic use, and time to oral diet all favor RALRC, while OR time favors ORC, depending on the diversion used. Further support came from the 2014 randomized trial between RALRC and ORC (Bochner
Washington, DC (UroToday.com) Following Dr. Parekh’s presentation on robotic cystectomy (RALRC), Dr. Bernard Bochner presented data in favor of open radical cystectomy (ORC) in today’s bladder cancer debate. He opened by declaring the poor state of current evidence, with 70 total publications on the topic, of which 23 have comparative data, and the majority are comprised of level 4 evidence. Despite this, the data demonstrates a high complication rates all around:
Washington, DC USA (UroToday.com) In today’s SUO-CTC scientific session at the 2015 Society of Urologic Oncology, Dr. Collin Dinney from MD Anderson Cancer Center viewed the state of novel intravesical therapies for non-muscle invasive bladder cancer (NMIBC).
Washington, DC USA (UroToday.com) Bladder urothelial carcinoma is the fourth most common non-cutaneous solid malignancy in men and the ninth most common in women. Muscle invasive bladder cancer (MIBC) accounts for 25% of total bladder cancer patients at presentation with a 5-year mortality rate of 50-75% after cystectomy.
The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
